Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
J Virol ; 97(11): e0138923, 2023 Nov 30.
Article in English | MEDLINE | ID: mdl-37888983

ABSTRACT

IMPORTANCE: Kaposi's sarcoma-associated herpesvirus (KSHV) is a cancer-causing human herpesvirus that establishes a persistent infection in humans. The lytic viral cycle plays a crucial part in lifelong infection as it is involved in the viral dissemination. The master regulator of the KSHV lytic replication cycle is the viral replication and transcription activator (RTA) protein, which is necessary and sufficient to push the virus from latency into the lytic phase. Thus, the identification of host factors utilized by RTA for controlling the lytic cycle can help to find novel targets that could be used for the development of antiviral therapies against KSHV. Using a proteomics approach, we have identified a novel interaction between RTA and the cellular E3 ubiquitin ligase complex RNF20/40, which we have shown to be necessary for promoting RTA-induced KSHV lytic cycle.


Subject(s)
Herpesvirus 8, Human , Host Microbial Interactions , Immediate-Early Proteins , Ubiquitin-Protein Ligases , Viral Proteins , Virus Activation , Virus Latency , Virus Replication , Humans , Herpesvirus 8, Human/growth & development , Herpesvirus 8, Human/physiology , Immediate-Early Proteins/metabolism , Protein Binding , Proteomics , Trans-Activators/metabolism , Ubiquitin-Protein Ligases/metabolism , Viral Proteins/metabolism
2.
Brain Res ; 1833: 148884, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38527712

ABSTRACT

Cerebral small vessel disease (cSVD) is a common neurological finding characterized by abnormalities of the small blood vessels in the brain. Previous research has established a strong connection between cSVD and stroke, as well as neurodegenerative disorders, notably Alzheimer's disease (AD) and other dementias. As the search for effective interventions continues, physical activity (PA) has emerged as a potential preventative and therapeutic avenue. This review synthesizes the human and animal literature on the influence of PA on cSVD, highlighting the importance of determining optimal exercise protocols, considering aspects such as intensity, duration, timing, and exercise type. Furthermore, the necessity of widening the age bracket in research samples is discussed, ensuring a holistic understanding of the interventions across varying pathological stages of the disease. The review also suggests the potential of exploring diverse biomarkers and risk profiles associated with clinically significant outcomes. Moreover, we review findings demonstrating the beneficial effects of PA in various rodent models of cSVD, which have uncovered numerous mechanisms of neuroprotection, including increases in neuroplasticity and integrity of the vasculature and white matter; decreases in inflammation, oxidative stress, and mitochondrial dysfunction; and alterations in amyloid processing and neurotransmitter signaling. In conclusion, this review highlights the potential of physical activity as a preventive strategy for addressing cSVD, offering insights into the need for refining exercise parameters, diversifying research populations, and exploring novel biomarkers, while shedding light on the intricate mechanisms through which exercise confers neuroprotection in both humans and animal models.


Subject(s)
Cerebral Small Vessel Diseases , Exercise , Neuroprotection , Cerebral Small Vessel Diseases/physiopathology , Humans , Exercise/physiology , Animals , Neuroprotection/physiology , Brain/physiopathology , Brain/pathology
SELECTION OF CITATIONS
SEARCH DETAIL